# Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

> **NCT01678976** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 13 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** BIA 2-093
- **DRUG:** Oxcarbazepine

## Key facts

- **NCT ID:** NCT01678976
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2002-04
- **Final completion:** 2002-04
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2015-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01678976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01678976, "Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01678976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*